ArchPoint Investors’s Amgen AMGN Stock Holding History

ArchPoint Investors’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,009	Closed	-$215K	–	72
2021 Q3	$215K	Buy	+1,009	New	+$232K	0.06%	101

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ArchPoint Investors's AMGN Position: Q4 2021 in Review

ArchPoint Investors sold out of Amgen (AMGN) in Q4 2021, closing a stake of 1,009 shares — an estimated $215K sold.

ArchPoint Investors first reported a position in AMGN in Q3 2021 and held it in 1 quarter. The position peaked at $215K in Q3 2021. 2,294 funds tracked by Wall St. Rank hold AMGN as of Q4 2021.

ArchPoint Investors reported no remaining Amgen position as of Q4 2021 after selling out during the quarter.
ArchPoint Investors sold 1,009 Amgen shares in Q4 2021, an estimated $215K.
ArchPoint Investors first reported a position in Amgen in Q3 2021 and held it in 1 quarter.
ArchPoint Investors's Amgen position peaked at $215K in Q3 2021.
2,294 funds tracked by Wall St. Rank held Amgen as of Q4 2021.

Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.